Skip to Main Content
Table 2.

Risk factors for response and survival after [90Y-DOTA]-TOC treatment

End pointRisk factor (unit)Odds ratio (unadjusted)P
Response to [90Y-DOTA]-TOC therapy Age (y) 1.02 (0.96-1.08) 0.56   
 Sex 0.50 (0.08-3.01) 0.45   
 Duration of disease (y) 1.06 (0.89-1.27) 0.51   
 Calcitonin (pg/mL) 1.00 (0.98-1.02) 0.90   
 Visual score 1.02 (0.41-2.53) 0.96   
      
End point
 
Risk factor (unit)
 
Hazard ratio (unadjusted)
 
P
 
Hazard ratio (adjusted)*
 
P
 
Survival from time of diagnosis Duration of disease (y) 0.74 (0.63-0.87) 0.0003 0.64 (0.51-0.81) 0.0003 
 Response 0.50 (0.16-1.51) 0.22 0.20 (0.05-0.81) 0.02 
 Age (y) 0.99 (0.96-1.03) 0.60 0.97 (0.93-1.01) 0.09 
 Cumulative activity (GBq) 0.34 (0.13-0.86) 0.02 0.45 (0.17-1.19) 0.11 
 Calcitonin (ng/mL) 1.01 (0.99-1.02) 0.32   
 Sex 0.67 (0.24-1.80) 0.43   
 Kidney toxicity 1.36 (0.49-3.78) 0.56   
Survival from first [90Y-DOTA]-TOC therapy Calcitonin (ng/mL) 1.01 (1.00-1.03) 0.03 1.02 (1.00-1.04) 0.007 
 Kidney toxicity 0.56 (0.19-1.70) 0.31 1.02 (1.00-1.04) 0.007 
 Cumulative activity (GBq) 0.41 (0.17-0.97) 0.04 0.24 (0.09-0.69) 0.008 
 Response 0.18 (0.05-0.61) 0.006 0.16 (0.04-0.63) 0.009 
 Age (y) 0.98 (0.94-1.02) 0.31 0.96 (0.93-1.00) 0.02 
 Duration of disease (y) 1.05 (0.97-1.14) 0.23   
 Sex 0.85 (0.30-2.44) 0.77   
Time to kidney toxicity Calcitonin (ng/mL) 1.01 (0.99-1.03) 0.26   
 Age (y) 1.04 (0.96-1.12) 0.34   
 Duration of disease (y) 0.89 (0.67-1.18) 0.41   
 Creatinine clearance (mL/min) 0.99 (0.96-1.02) 0.47   
 Sex 0.50 (0.04-6.11) 0.59   
 Cumulative activity (GBq) 1.16 (0.30-4.46) 0.83   
End pointRisk factor (unit)Odds ratio (unadjusted)P
Response to [90Y-DOTA]-TOC therapy Age (y) 1.02 (0.96-1.08) 0.56   
 Sex 0.50 (0.08-3.01) 0.45   
 Duration of disease (y) 1.06 (0.89-1.27) 0.51   
 Calcitonin (pg/mL) 1.00 (0.98-1.02) 0.90   
 Visual score 1.02 (0.41-2.53) 0.96   
      
End point
 
Risk factor (unit)
 
Hazard ratio (unadjusted)
 
P
 
Hazard ratio (adjusted)*
 
P
 
Survival from time of diagnosis Duration of disease (y) 0.74 (0.63-0.87) 0.0003 0.64 (0.51-0.81) 0.0003 
 Response 0.50 (0.16-1.51) 0.22 0.20 (0.05-0.81) 0.02 
 Age (y) 0.99 (0.96-1.03) 0.60 0.97 (0.93-1.01) 0.09 
 Cumulative activity (GBq) 0.34 (0.13-0.86) 0.02 0.45 (0.17-1.19) 0.11 
 Calcitonin (ng/mL) 1.01 (0.99-1.02) 0.32   
 Sex 0.67 (0.24-1.80) 0.43   
 Kidney toxicity 1.36 (0.49-3.78) 0.56   
Survival from first [90Y-DOTA]-TOC therapy Calcitonin (ng/mL) 1.01 (1.00-1.03) 0.03 1.02 (1.00-1.04) 0.007 
 Kidney toxicity 0.56 (0.19-1.70) 0.31 1.02 (1.00-1.04) 0.007 
 Cumulative activity (GBq) 0.41 (0.17-0.97) 0.04 0.24 (0.09-0.69) 0.008 
 Response 0.18 (0.05-0.61) 0.006 0.16 (0.04-0.63) 0.009 
 Age (y) 0.98 (0.94-1.02) 0.31 0.96 (0.93-1.00) 0.02 
 Duration of disease (y) 1.05 (0.97-1.14) 0.23   
 Sex 0.85 (0.30-2.44) 0.77   
Time to kidney toxicity Calcitonin (ng/mL) 1.01 (0.99-1.03) 0.26   
 Age (y) 1.04 (0.96-1.12) 0.34   
 Duration of disease (y) 0.89 (0.67-1.18) 0.41   
 Creatinine clearance (mL/min) 0.99 (0.96-1.02) 0.47   
 Sex 0.50 (0.04-6.11) 0.59   
 Cumulative activity (GBq) 1.16 (0.30-4.46) 0.83   

NOTE: 95% confidence intervals are presented in parentheses.

*

Adjusted for all other covariates in the list.

Natural logarithm of cumulative activity.

Close Modal

or Create an Account

Close Modal
Close Modal